ES2617241T3 - Derivados de triazol fusionados como moduladores de gama secretasa - Google Patents
Derivados de triazol fusionados como moduladores de gama secretasa Download PDFInfo
- Publication number
- ES2617241T3 ES2617241T3 ES13729269.4T ES13729269T ES2617241T3 ES 2617241 T3 ES2617241 T3 ES 2617241T3 ES 13729269 T ES13729269 T ES 13729269T ES 2617241 T3 ES2617241 T3 ES 2617241T3
- Authority
- ES
- Spain
- Prior art keywords
- nmr
- phenyl
- methyl
- methoxy
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- -1 R3 is H Chemical group 0.000 abstract description 42
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract description 6
- 150000001412 amines Chemical class 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 50
- 238000005481 NMR spectroscopy Methods 0.000 description 49
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- UXHMGTYELGTNSJ-UHFFFAOYSA-N triazole-1-carboxamide Chemical compound NC(=O)N1C=CN=N1 UXHMGTYELGTNSJ-UHFFFAOYSA-N 0.000 description 11
- GOLCAGIALURFLH-UHFFFAOYSA-N triazolo[1,5-a]pyridine-3-carboxamide Chemical compound C1=CC=CC2=C(C(=O)N)N=NN21 GOLCAGIALURFLH-UHFFFAOYSA-N 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- MPSUGQWRVNRJEE-UHFFFAOYSA-N triazol-1-amine Chemical compound NN1C=CN=N1 MPSUGQWRVNRJEE-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- YRMBLGBOLGVWEN-UHFFFAOYSA-N 6-(4-chlorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-4h-pyrrolo[1,2-c]triazole-3-carboxamide Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(=O)C(=C1CC2)N=NN1C2C1=CC=C(Cl)C=C1 YRMBLGBOLGVWEN-UHFFFAOYSA-N 0.000 description 1
- SSICOMJOGLUENS-UHFFFAOYSA-N 7-(2-chloro-4-fluorophenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=C2CCCC(C=3C(=CC(F)=CC=3)Cl)N2N=N1 SSICOMJOGLUENS-UHFFFAOYSA-N 0.000 description 1
- QKVBVKKRIQAZRW-UHFFFAOYSA-N 7-(2-chloro-4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=C1CCC2)N=NN1C2C1=CC=C(F)C=C1Cl QKVBVKKRIQAZRW-UHFFFAOYSA-N 0.000 description 1
- UIFWKTFIEUXERK-UHFFFAOYSA-N 7-(4-chlorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=C1CCC2)N=NN1C2C1=CC=C(Cl)C=C1 UIFWKTFIEUXERK-UHFFFAOYSA-N 0.000 description 1
- LBZIURPGQYQIMU-UHFFFAOYSA-N 7-(4-chlorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-6,7-dihydro-4h-triazolo[5,1-c][1,4]oxazine-3-carboxamide Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=O)C(=C1COC2)N=NN1C2C1=CC=C(Cl)C=C1 LBZIURPGQYQIMU-UHFFFAOYSA-N 0.000 description 1
- WCAHWCFAFJGORB-UHFFFAOYSA-N 7-(4-chlorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-n-methyl-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridine-3-carboxamide Chemical compound COC1=CC(N(C)C(=O)C2=C3CCCC(N3N=N2)C=2C=CC(Cl)=CC=2)=CC=C1N1C=NC(C)=C1 WCAHWCFAFJGORB-UHFFFAOYSA-N 0.000 description 1
- GVWRXIYQCGLQHH-UHFFFAOYSA-N 7-(4-fluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridine-3-carboxylic acid Chemical compound C1CCC2=C(C(=O)O)N=NN2C1C1=CC=C(F)C=C1 GVWRXIYQCGLQHH-UHFFFAOYSA-N 0.000 description 1
- ATCKILIMACMMSG-UHFFFAOYSA-N 7-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=C1CCC2)N=NN1C2C1=CC=C(F)C=C1 ATCKILIMACMMSG-UHFFFAOYSA-N 0.000 description 1
- CWNNNWXHCMTMKI-UHFFFAOYSA-N 7-[3-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridine-3-carboxylic acid Chemical compound C1CCC2=C(C(=O)O)N=NN2C1C1=CC=CC(C(F)(F)F)=C1 CWNNNWXHCMTMKI-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HEYKQRIUOISJFF-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-7-[2-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=C1CCC2)N=NN1C2C1=CC=CC=C1C(F)(F)F HEYKQRIUOISJFF-UHFFFAOYSA-N 0.000 description 1
- FXCBLUSFRKDIHI-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-7-[3-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydrotriazolo[1,5-a]pyridin-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=C1CCC2)N=NN1C2C1=CC=CC(C(F)(F)F)=C1 FXCBLUSFRKDIHI-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672436P | 2012-07-17 | 2012-07-17 | |
| US201261672436P | 2012-07-17 | ||
| EP12176726 | 2012-07-17 | ||
| EP20120176726 EP2687528A1 (en) | 2012-07-17 | 2012-07-17 | Fused triazole derivatives as gamma secretase modulators |
| PCT/EP2013/001774 WO2014012614A1 (en) | 2012-07-17 | 2013-06-14 | Fused triazole derivatives as gamma secretase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2617241T3 true ES2617241T3 (es) | 2017-06-15 |
Family
ID=46514224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13729269.4T Active ES2617241T3 (es) | 2012-07-17 | 2013-06-14 | Derivados de triazol fusionados como moduladores de gama secretasa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9527853B2 (enExample) |
| EP (2) | EP2687528A1 (enExample) |
| JP (1) | JP6229717B2 (enExample) |
| CN (1) | CN104640859B (enExample) |
| AU (1) | AU2013292782B2 (enExample) |
| CA (1) | CA2879195C (enExample) |
| ES (1) | ES2617241T3 (enExample) |
| WO (1) | WO2014012614A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016028971A1 (en) * | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| JP6831372B2 (ja) * | 2015-09-09 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋ピペリジン誘導体 |
| JP7012715B2 (ja) * | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| EP3484884B1 (en) * | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| CN109476670B (zh) * | 2016-10-04 | 2022-06-28 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| CN107200737B (zh) * | 2017-06-29 | 2019-03-26 | 武汉药明康德新药开发有限公司 | 叔丁氧羰基-3-(羟甲基)-[1,2,3]三氮唑[1,5-a]哌啶-6-酰胺制法 |
| CN116925024B (zh) * | 2023-07-24 | 2025-07-25 | 阜阳欣奕华制药科技有限公司 | 一种4,6-二甲基阔马酸甲酯的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| EP1628666B1 (en) * | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| PL1992618T3 (pl) * | 2006-03-09 | 2012-06-29 | Eisai R&D Man Co Ltd | Policykliczna pochodna cynamidowa |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| JP2010538068A (ja) | 2007-09-06 | 2010-12-09 | シェーリング コーポレイション | ガンマセクレターゼモジュレーター |
| JP2011506335A (ja) * | 2007-12-06 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| CA2707492A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| JP2012051806A (ja) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| TW201035101A (en) * | 2009-02-26 | 2010-10-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compound |
| US20120142672A1 (en) * | 2009-07-13 | 2012-06-07 | Tatsuki Koike | Heterocyclic compound and use thereof |
| AU2011206635B2 (en) | 2010-01-15 | 2015-01-22 | Cellzome Limited | Novel substituted triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| EP2611805A1 (en) * | 2010-09-02 | 2013-07-10 | Takeda Pharmaceutical Company Limited | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
-
2012
- 2012-07-17 EP EP20120176726 patent/EP2687528A1/en not_active Withdrawn
-
2013
- 2013-06-14 JP JP2015521985A patent/JP6229717B2/ja active Active
- 2013-06-14 AU AU2013292782A patent/AU2013292782B2/en active Active
- 2013-06-14 CA CA2879195A patent/CA2879195C/en active Active
- 2013-06-14 EP EP13729269.4A patent/EP2875025B1/en active Active
- 2013-06-14 US US14/406,386 patent/US9527853B2/en active Active
- 2013-06-14 WO PCT/EP2013/001774 patent/WO2014012614A1/en not_active Ceased
- 2013-06-14 ES ES13729269.4T patent/ES2617241T3/es active Active
- 2013-06-14 CN CN201380038142.0A patent/CN104640859B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2875025A1 (en) | 2015-05-27 |
| CN104640859B (zh) | 2017-03-01 |
| JP2015522592A (ja) | 2015-08-06 |
| EP2687528A1 (en) | 2014-01-22 |
| US9527853B2 (en) | 2016-12-27 |
| CA2879195C (en) | 2021-02-16 |
| CN104640859A (zh) | 2015-05-20 |
| US20150183790A1 (en) | 2015-07-02 |
| AU2013292782A1 (en) | 2015-02-26 |
| WO2014012614A1 (en) | 2014-01-23 |
| AU2013292782B2 (en) | 2017-07-13 |
| EP2875025B1 (en) | 2016-11-30 |
| JP6229717B2 (ja) | 2017-11-15 |
| CA2879195A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6951767B2 (ja) | 抗癌薬として使用される複素環式化合物 | |
| EP2791138B1 (en) | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors | |
| AU2010281368B2 (en) | Novel bicyclic urea compounds | |
| ES2553753T3 (es) | Compuestos de quinuclidina como ligandos del receptor nicotínico de acetilcolina alfa7 | |
| ES2684268T3 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| ES2829400T3 (es) | Inhibidores tricíclicos de Rho cinasa | |
| EP4705281A1 (en) | Compounds for treating cancer | |
| CA2383077A1 (en) | Androgen receptor modulator compounds and methods | |
| CA2434727A1 (en) | Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds | |
| AU2024200781A1 (en) | Substituted fused bi- or tri-heterocyclic compounds as ehmt2 inhibitors | |
| CA2568804A1 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists | |
| ES2503794T3 (es) | Inhibidores de la actividad Akt | |
| MD3658552T2 (ro) | Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil | |
| EA036137B1 (ru) | Производные тетрагидроизохинолина | |
| TW202241413A (zh) | 吡唑並喹唑啉類化合物、其製備方法及用途 | |
| CN121464124A (zh) | 芳香酰胺类衍生物及其制备方法和用途 | |
| AU2016214802B2 (en) | Diaza-benzofluoranthrene compounds | |
| CN121100117A (zh) | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 | |
| CA2631853A1 (en) | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | |
| PT1492796E (pt) | ¿derivados de isoxazolina substituídos com amino e sua utilização como antidepressivos¿ | |
| TW202102494A (zh) | 抑制環amp-反應元件-結合蛋白(creb) | |
| AU2021319597A1 (en) | Heterocyclic compound as BCL-2 inhibitor | |
| Dou et al. | Synthesis and biological evaluation of novel pyrimido [4, 5-b] quinoline-2, 4-dione derivatives as MDM2 ubiquitin ligase inhibitors | |
| EP4724427A1 (en) | A process of preparation of an antibacterial compound and its intermediates thereof | |
| CN119899178A (zh) | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |